

Effective suppression of donor specific antibody production by Cathepsin S inhibitors in a mouse transplantation model

Kaori Kubo, Yuka Kawato, Koji Nakamura, Yutaka Nakajima, Terry Y Nakagawa, Kaori Hanaoka, Shinsuke Oshima, Hidehiko Fukahori, Masamichi Inami, Tatsuaki Morokata, Yasuyuki Higashi



www.elsevier.com/locate/ejphar

PII: S0014-2999(18)30524-7
DOI: <https://doi.org/10.1016/j.ejphar.2018.09.007>
Reference: EJP71976

To appear in: *European Journal of Pharmacology*

Received date: 22 June 2018
Revised date: 16 August 2018
Accepted date: 5 September 2018

Cite this article as: Kaori Kubo, Yuka Kawato, Koji Nakamura, Yutaka Nakajima, Terry Y Nakagawa, Kaori Hanaoka, Shinsuke Oshima, Hidehiko Fukahori, Masamichi Inami, Tatsuaki Morokata and Yasuyuki Higashi, Effective suppression of donor specific antibody production by Cathepsin S inhibitors in a mouse transplantation model, *European Journal of Pharmacology*, <https://doi.org/10.1016/j.ejphar.2018.09.007>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Effective suppression of donor specific antibody production by Cathepsin S inhibitors in a mouse transplantation model

Kaori Kubo^{a}, Yuka Kawato^a, Koji Nakamura^a, Yutaka Nakajima^a, Terry Y Nakagawa^b, Kaori Hanaoka^a, Shinsuke Oshima^a, Hidehiko Fukahori^a, Masamichi Inami^a, Tatsuaki Morokata^a, Yasuyuki Higashi^a*

^aDrug Discovery Research, Astellas Pharma Inc., 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan

^bAstellas Research Institute of America LLC, 8045 Lamon Ave., Skokie, Illinois 60077, USA

***Corresponding author:** Kaori Kubo, Drug Discovery Research, Astellas Pharma Inc., 21

Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan. **Tel:** +81-29-829-6135, **Fax:**

+81-29-852-2972. **E-mail:** kaori.kubo@astellas.com

Abstract

Donor-specific antibodies (DSA) are a major risk factor for antibody-mediated rejection (ABMR) in solid organ transplantation, and ABMR remains a medical challenge. Therefore, effective anti-ABMR therapies are needed to improve overall graft survival. Cathepsin S (Cat S) is an essential protease for antigen peptide loading onto lysosomal/endosomal major histocompatibility complex (MHC) class II molecules to promote antigen presentation. Cat S deficiency produces immuno-deficient phenotypes including a suppressed humoral immune response, and Cat S

Download English Version:

<https://daneshyari.com/en/article/10158439>

Download Persian Version:

<https://daneshyari.com/article/10158439>

[Daneshyari.com](https://daneshyari.com)